~~<i id='6488811849'><strike id='6488811849'><tt id='6488811849'><pre id='6488811849'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：comprehensive 2025-10-02 04:07:29 - browse：29443

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Humana’s losses in Medicare Advantage tank its stock

hotspot

entertainment

hotspot

entertainment

Wikipedia

PatGreenhouse/GlobeStaffMORRISVILLE,N.C.—TenminutesfromtheRaleighairport,thefutureofbiotechisunderco

WSS

Senate panel eyes new effort on drug shortages

Was Amgen transparent enough on FDA's concern on cancer drug?

Bristol 'take

Vertex non

Reconstructing family trees of blood cells may help predict disease

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

knowledge

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

What to expect at HLTH 2023, the health care industry conference

Trump demands the U.S. pay no more for drugs than other countries … again

Was Amgen transparent enough on FDA's concern on cancer drug?

How to save PrEP access — and even expand it

A virus, fished out of a lake, may have saved a man’s life

In age of alternative facts, a scholarly course on calling out crap

FDA rejects Alnylam's heart disease treatment over insufficient data

As demand for Covid shots wanes, Moderna seeks its next success

Biogen walks away from Aduhelm, years after polarizing approval

entertainment

Histogen: Failed biotech offers rare public look inside

The Affordable Care Act has saved billions in health care costs

Bernie Sanders is gearing up to subpoena pharma CEOs

Analysis of telehealth claims data suggest service duplication

Chan Zuckerberg Biohub Chicago to focus on inflammation

Histogen: Failed biotech offers rare public look inside

entertainment

hotspot

entertainment

Wikipedia